# A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07407933/  
OnCo record `nct07407933` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of YL201 and Atezolizumab in small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.

## Summary

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07407933 by MediLink Therapeutics (Suzhou) Co., Ltd., with 118 participants planned, started 2026-03-31 and due to reach its primary completion in 2028-11. Interventions recorded: YL201 and Atezolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07407933
- Phase: 1/2
- Setting: A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Enrolled: 118

## Sources

- ClinicalTrials.gov NCT07407933: https://clinicaltrials.gov/study/NCT07407933

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [YL201](https://onco.cc/drugs/yl201/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct07407933.json